FOXO3A Mouse Monoclonal Antibody
- Known as:
- FOXO3A Mouse Monoclonal Antibody
- Catalog number:
- BIN-002309-M05
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- FOXO3A Mouse Monoclonal Antibody
Related genes to: FOXO3A Mouse Monoclonal Antibody
- Gene:
- FOXO3 NIH gene
- Name:
- forkhead box O3
- Previous symbol:
- FKHRL1, FOXO3A
- Synonyms:
- AF6q21, FOXO2
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-23
- Date modifiied:
- 2015-08-25
Related products to: FOXO3A Mouse Monoclonal Antibody
Related articles to: FOXO3A Mouse Monoclonal Antibody
- Osteosarcoma is a malignant bone tumor that occurs in adolescents and for which surgical resection and chemotherapy are the treatments of first choice. However, tumor cell metastasis and the toxic effects of chemotherapeutic agents bring great challenges to the treatment of osteosarcoma. Fisetin, a dietary flavonoid derived from vegetables and fruits, plays a therapeutic role in many cancers, but its role and underlying mechanism on osteosarcoma remain unrevealed. This study found that fisetin significantly inhibited the proliferation of osteosarcoma cells and organoids. RNA sequencing revealed that forkhead box O3 (FOXO3) may be a key target of fisetin in its anti-osteosarcoma activity, which was also verified by immunofluorescence. siFOXO3 reversed the effects of fisetin on proliferation, apoptosis, and migration of osteosarcoma cells. Fisetin exerts its effects by targeting the ROS/FOXO3 pathway to promote the binding of FOXO3 to the microtubule-associated protein light chain 3 (LC3) promoter, thereby upregulating LC3 levels and inducing autophagy. Subsequently, activated autophagy further triggers ferroptosis, while silencing LC3 reversed fisetin-induced ferroptosis. In vivo, fisetin inhibited tumor growth while promoting FOXO3 and LC3, and inhibiting SLC7A11 protein expression. Therefore, fisetin-induced autophagy in osteosarcoma cells may be associated with the reactive oxygen species (ROS)/FOXO3 axis, thereby promoting ferroptosis. These findings highlight fisetin's potential as a unique therapy for osteosarcoma. - Source: PubMed
Publication date: 2026/05/07
Hu YujieWei LanyiMeng JingjingXiang DanfengZhang XiangqiZhang JingxianYang QuanjunZhou YangyunXu LingyanWang MengyueChen JunjunHan Yonglong - Sickle cell disease (SCD) is a severe monogenic red blood cell (RBC) disorder that follows a simple Mendelian mode of inheritance. SCD is characterized by hemoglobin S polymerization under deoxygenated conditions, leading to chronic hemolysis and vaso-occlusive complications. Increasing evidence indicates that oxidative stress plays a central pathogenic role in SCD complications. Forkhead box O3 (FOXO3) is a key transcription factor involved in different cellular mechanisms, including apoptosis, autophagy, and cytoprotective signaling cascades. FOXO3, through its transcriptional modulation of enzymes such as superoxide dismutase, glutathione peroxidase, and catalase, reduces reactive oxygen species burden, delays hemolysis, and contributes to RBC longevity. Beyond its antioxidant defense properties, FOXO3 interacts with other key molecular pathways, such as nuclear factor erythroid 2-related factor 2, nuclear factor kappa B, AMP-activated protein kinase, and sirtuin 1, which modulate vascular inflammation, nitric oxide bioavailability, and systemic redox homeostasis. Thus, by promoting antioxidant defense and facilitating autophagy, FOXO3 emerges as both a biomarker and a promising therapeutic target in SCD. This review provides key findings from the existing literature and precisely explores FOXO3's role in cellular stress responses, antioxidant defense, fetal hemoglobin production, erythropoiesis, and RBC longevity, as well as their implications for disease severity and therapeutic strategies in SCD. Future studies focusing on patient-specific FOXO3 activity by precision modulation and multi-omics sequencing will be essential to fully harness FOXO3's potential to achieve beneficial outcomes for individuals with SCD. - Source: PubMed
Publication date: 2026/04/29
Pavitra EluriKumbhakar MeenooKim ByeongsuGupta Vivek KumarGupta PragatiLee Jeong-HwanHan Young-KyuBhaskar LvksRaju Ganji Seeta RamaHuh Yun Suk - This study explores the mechanism of propofol in autologous orthotopic liver transplantation (AOLT)-insulted kidney injury. - Source: PubMed
Publication date: 2026/04/20
Jin GangTang XiaolinGu BeibeiZhou Jiaojie - Hyperlipidemia (HLP) is a prevalent metabolic disorder that induces myocardial injury through prolonged oxidative stress. Cardamonin (CAR), a natural chalcone from the Zingiberaceae family, is recognised for its antioxidant and anti-inflammatory activities; however, its specific role and underlying mechanisms in cardiovascular protection against HLP remain to be fully elucidated. This study aimed to investigate the protective effects of CAR on HLP-induced cardiac damage. - Source: PubMed
Publication date: 2026/05/05
Yang WenjiaJiao QiuhongChen JiahongXu LongwuHan HaoyuFeng JunjieWang XinyuWang TaoMeng Chun - Flap transplantation is a key approach for soft tissue reconstruction, but distal ischaemic necrosis remains a major limitation. Intravenous drug administration is preferred for treating ischaemic flaps; however, insufficient local drug concentrations before vascular reconstruction often reduce its efficacy. To address this, we developed a novel recombinant protein, RGD-Latcripin-7A (R-L), by fusing the autophagy-activating, ischaemia-protective protein Latcripin-7A (L) to the angiogenesis-targeting peptide RGD. - Source: PubMed
Publication date: 2026/05/01
Zhang XuziYang NingningChen ZhixuanHuang YifanHuang YingyingShi JingweiXu HengruiZhu XuweiXia WeijieLi ZhenglinGao WeiyangQi JianjunXiao JianZhou Kailiang